Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evandro de Azambuja

Showing results (121-130 of 259) with videos related to

Pageof 26
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2020
Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass IndexChristine Desmedt, Marco Fornili, Florian Clatot, et al.
BMJ Supportive & Palliative Care|December 18, 2020
Malignant bowel obstruction: effectiveness and safety of systemic chemotherapyRafael Caparica, Larissa Amorim, Paulo Amaral, et al.
Cancer Treatment Reviews|November 29, 2024
Expert consensus on the prevention of brain metastases in patients with HER2-positive breast cancerVolkmar Müller, Thomas Bachelot, Giuseppe Curigliano, et al.
Journal of Cancer Research and Clinical Oncology|July 22, 2022
Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysisDiogo Martins-Branco, Guilherme Nader-Marta, Ana Tecic Vuger, et al.
Journal of the National Cancer Institute|March 31, 2021
Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast CancerNuria Chic, Stephen J Luen, Paolo Nuciforo, et al.
Breast Cancer Research and Treatment|December 29, 2015
Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experienceOtto Metzger-Filho, Evandro de Azambuja, Marion Procter, et al.
Breast Cancer Research and Treatment|October 13, 2019
A pooled analysis of the cardiac events in the trastuzumab adjuvant trialsEvandro de Azambuja, Noam Ponde, Marion Procter, et al.
AIDS (London, England)|January 4, 2021
Impact of HIV infection on baseline characteristics and survival of women with breast cancerMariana Brandão, Marco Bruzzone, Maria-Alice Franzoi, et al.
Journal of the National Cancer Institute|April 4, 2026
The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trialElisa Agostinetto, Gabriella Gentile, Faye Samy, et al.
International Journal of Cancer|November 5, 2020
STAT3 activation in HER2-positive breast cancers: Analysis of data from a large prospective trialAmir Sonnenblick, Dominique Agbor-Tarh, Evandro de Azambuja, et al.
Pageof 26

Showing results (121-130 of 259) with videos related to

Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2020
Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass IndexChristine Desmedt, Marco Fornili, Florian Clatot, et al.
BMJ Supportive & Palliative Care|December 18, 2020
Malignant bowel obstruction: effectiveness and safety of systemic chemotherapyRafael Caparica, Larissa Amorim, Paulo Amaral, et al.
Cancer Treatment Reviews|November 29, 2024
Expert consensus on the prevention of brain metastases in patients with HER2-positive breast cancerVolkmar Müller, Thomas Bachelot, Giuseppe Curigliano, et al.
Journal of Cancer Research and Clinical Oncology|July 22, 2022
Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysisDiogo Martins-Branco, Guilherme Nader-Marta, Ana Tecic Vuger, et al.
Journal of the National Cancer Institute|March 31, 2021
Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast CancerNuria Chic, Stephen J Luen, Paolo Nuciforo, et al.
Breast Cancer Research and Treatment|December 29, 2015
Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experienceOtto Metzger-Filho, Evandro de Azambuja, Marion Procter, et al.
Breast Cancer Research and Treatment|October 13, 2019
A pooled analysis of the cardiac events in the trastuzumab adjuvant trialsEvandro de Azambuja, Noam Ponde, Marion Procter, et al.
AIDS (London, England)|January 4, 2021
Impact of HIV infection on baseline characteristics and survival of women with breast cancerMariana Brandão, Marco Bruzzone, Maria-Alice Franzoi, et al.
Journal of the National Cancer Institute|April 4, 2026
The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trialElisa Agostinetto, Gabriella Gentile, Faye Samy, et al.
International Journal of Cancer|November 5, 2020
STAT3 activation in HER2-positive breast cancers: Analysis of data from a large prospective trialAmir Sonnenblick, Dominique Agbor-Tarh, Evandro de Azambuja, et al.
Pageof 26